TEL: +86 571 56623320 EMAIL: [email protected]
|
Technical Q & A
SL2304Hu Human Interferon β Antibody ELISA Kit MS suitability
|
| Product | Human Interferon β Antibody ELISA Kit |
| Cat. No. | SL2304Hu |
The customer is a doctoral researcher at the College of Pharmacy, University of Baghdad, Iraq, conducting a comparative immunogenicity study in patients with multiple sclerosis (MS) receiving Cinnovex® (30 µg, intramuscular injection, once weekly) and Recigen® (22 or 44 µg, subcutaneous injection, three times weekly), and asks:
1. Does this kit specifically detect binding antibodies against human IFN-β1a? Is the coated antigen recombinant human IFN-β1a or another form? Is it suitable for comparing binding antibodies induced by Cinnovex and Recigen treatment? Has it been validated with serum from MS patients treated with IFN-β1a?
2. Does residual IFN-β1a in patient serum interfere with antibody detection and cause false negatives? Has drug tolerance been evaluated? What is the maximum tolerated IFN-β1a concentration? Is it recommended to collect serum immediately before the next dose? Is there an acid dissociation procedure to reduce drug interference? What is the antibody reference standard used to generate the pg/mL calibration curve? Can you provide validation data, a recommended positive cutoff, and published studies using this kit for interferon β immunogenicity testing?
1. This kit is used to detect binding anti-drug antibodies (ADAs) against human IFN-β1a. The antigen coated on the microplate is recombinant human IFN-β1a (rhIFN-β1a). This kit is suitable for head-to-head comparison of anti-IFN-β1a binding antibodies induced by Cinnovex® and Recigen®; the amino acid sequence of IFN-β1a in both drugs is identical and matches the coated antigen, and differences in dose, route of administration, and formulation are not expected to cause systematic assay bias due to antigen mismatch. This kit has only been validated using healthy human serum; clinical applicability has not yet been validated using serum from MS patients receiving IFN-β1a treatment.
2. Residual free IFN-β1a in serum can interfere with ADA detection and may lead to false negatives, because free drug forms immune complexes with ADAs, preventing ADA binding to the immobilized antigen. Drug tolerance was not evaluated. It is recommended to collect trough serum samples immediately before the next dose; this is the preferred sampling strategy to minimize circulating free IFN-β1a. For samples with high residual drug levels, an acid dissociation pretreatment protocol can be used; however, the applicability of this method must be validated for the specific sample and this kit. The reference standard used to generate the pg/mL calibration curve is an in-house polyclonal anti-IFN-β1a reference antibody. Please note that this unit represents relative quantification; there is currently no WHO international standard for anti-IFN-β1a ADAs, and the quantitative results of this kit cannot be directly compared or interchanged with values from other platforms.
· Sample type: serum; the kit validation used only healthy human serum, and clinical applicability has not been validated in serum from MS patients
· Other limitations: for the detection of binding ADAs against human IFN-β1a; the coating antigen is rhIFN-β1a; the Cinnovex/Recigen head-to-head comparison is based on the two having identical IFN-β1a amino acid sequences and matching the coating antigen; drug tolerance was not evaluated; it is recommended to collect trough concentration serum before the next dose; samples with high residual drug can be pretreated with acid dissociation but must be validated by the user; pg/mL is relative quantification, there is no WHO international standard, and results cannot be directly compared or interchanged with other platforms
+86 571 56623320
[email protected]
SUNLONG BIOTECH

Scan Wechat Qrcode
